Global Cough And Cold Preparations Market

The respiratory disposables market consists of sales of respiratory disposables and related services. Respiratory disposables include disposable resuscitators, disposable masks, disposable tubes, and other consumables and accessories. The main types of respiratory disposables are masks, tubes, inhalers, and others. A mask is a piece of cloth or other material that is personal protective equipment and intended for medical purposes. These are used for disease indications such as asthma, a chronic obstructive pulmonary disorder, tuberculosis, lung cancer, and other chronic respiratory diseases. The applications involved in adult, pediatric and neonatal. The various end-users are hospitals, clinics, ambulatory care centers, and others. The global respiratory disposables market size is expected to grow from $2.45 billion in 2021 to $2.76 billion in 2022 at a compound annual growth rate (CAGR) of 12.8%. The global respiratory disposable market is expected to grow to $4.24 billion in 2026 at a CAGR of 11.3%. The high prevalence rate of respiratory diseases globally is driving the respiratory disposables market. Excessive smoking, exposure to toxic materials, adverse climate conditions, and air pollution are some of the main causes which are leading to a rise in respiratory diseases such as asthma, lung cancer, Chronic Obstructive Pulmonary Disease (COPD), and obstructive sleep apnea (OSA). According to a study, around 65 million people suffer from COPD and around 3 million people die every year because of this disease. It was also reported that around 334 million people suffer from asthma diseases caused by air pollution as well as tobacco smoke, toxic disposable devices. These factors are increasing the demand for the treatment of respiratory ailments, thus driving the respiratory diseases market. The respiratory disposables market is being restrained due to stringent regulatory policies. Regulatory agencies and governments across various countries are imposing stringent restrictions on product approval and launch, this is limiting the market growth. For instance, FDA banned Amphastar Pharmaceutical’s Primatene product, an albuterol CFC inhaler for asthma because ozone-depleting chlorofluorocarbon (CFC) propellants have depleted the ozone layer. The FDA rejected Amphastar’s first attempt to bring a reformulated version of Primatene mist to market. The FDA rejected another application for Primatene Mist. Which resulted in a rise in development costs and potential sales loss due to delays in product launch, thus restraining the Respiratory disposables market. Rapid advances in technology are driving innovation in respiratory disposable manufacturing. Areas of particular development are likely to be AIR gel technology, wearable technologies, and 3D printing technology. These technologies are being used in the manufacturing of respiratory disposables, resulting in higher productivity, lower costs, and higher margins. Companies in this market are increasingly focusing on AIR gel technology, in which gel is incorporated into the bag on the edges of the mask which helps to the protection of the skin and creates a bridge to minimize the irritation of the skin and for effective sealing. For example, Vyair medical prepared Veraseal 2 disposable mask, used for acute care with AIR gel technology and advantage of vented and non-vented versions. Similarly, Sleepnet prepared Mojo ventilation masks with Airgel technology. In the USA, occupational safety and health administration (OSHA) regulates all respiratory medical equipment, guidelines for which are specified in 29 CFR 1910. 134. Under OSHA, the national institute for occupational safety and health/national personal protective technology laboratory (NIOSH/ NPPTL) provides a market approval certificate and FDA approves the product for marketing. Before market approval, all the medical devices should be analyzed appropriately by performing a compatibility test within a hospital environment. They are tested on an Electrical bench and Non-clinical performance testing is also required. Moreover, proper software verification, validation, and hazard analysis must be performed. Labels on the devices are required to include the purpose of the device. In 2021, Medline a Netherland-based medical device company acquired the Hudson RCI brand of respiratory consumables from Teleflex. The acquisition helps Medline's offerings, enlarging the respiratory environment with the highly regarded Hudson RCI products and opening extra opportunities for development and help to customers. Teleflex is a US-based company global provider of medical technologies designed to develop the health and quality of people's lives. Major players in the respiratory disposables market are Fisher & Paykel, Becton Dickinson Company, Ambu A/S, Smiths Medical, Armstrong Medical, Teleflex, Philips Respironics, Besmed, ResMed, and Dynarex. Asia Pacific was the largest region in the respiratory disposables and equipment market in 2021. Western Europe was the second-largest region in the global respiratory disposables market. The regions covered in the global respiratory disposables market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory disposables market include Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, and Australia. The global respiratory disposables market is segmented - 1) By Type: Masks, Tubes, Inhalers, Others 2) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Others 3) By Disease Indication: Asthma, Chronic Obstructive Pulmonary Disorder, Tuberculosis, Lung Cancer, Others 4) By Application: Adult, Pediatric and Neonatal

The respiratory devices and equipment (diagnostic) market consists of sales of diagnostic respiratory devices and equipment and related services by entities (organizations, sole traders, and partnerships) that manufacture respiratory devices and equipment. Respiratory devices and equipment are used in the diagnosis of respiratory disorders such as asthma, cystic fibrosis, and chronic obstructive pulmonary disease. Only goods and services traded between entities or sold to end consumers are included. The main products of the diagnostic respiratory devices and equipment market are instruments and devices, assays, and reagents. The respiratory instruments and devices are used to diagnose respiratory disorders. The test type included is traditional diagnostic tests, mechanical tests, imaging tests, and molecular diagnostic tests that are used to diagnose chronic obstructive pulmonary disease, lung cancer, asthma, tuberculosis, and other diseases. These are used in hospital/clinical laboratories, physician offices, reference laboratories, and other end users. The global respiratory devices and equipment (diagnostic) market size is expected to grow from $6.36 billion in 2021 to $6.93 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The global diagnostic respiratory devices and equipment market size is expected to grow to $9.35 billion in 2026 at a CAGR of 7.8%. The increasing prevalence of various respiratory diseases contributed to the global respiratory devices and equipment market growth by increasing the use of diagnostic devices and equipment for diagnosis and treatment. Diseases such as chronic obstructive pulmonary disease (COPD) are more prevalent in the geriatric population. COPD is a type of obstructive lung disease that results in long-term breathing problems. For instance, in June 2021, according to the world health organization data, chronic obstructive pulmonary disease is the third disease on the list of causing death in the world. There were about 3.23 million deaths that are caused by COPD in 2019. Thus, the increased number of such cases has surged the demand for diagnostic devices and equipment, therefore driving the market’s growth. Stringent regulatory practices are expected to negatively impact the growth of diagnostic respiratory devices in the forecast period. In the USA, respiratory devices undergo a strict approval process as they come under Class III devices (that pose a significant risk to patients) as per the Food and Drug Administration (FDA) classification of medical devices. These devices require clinical evidence that supports their intended use unlike, Class I and II devices, to receive marketing approval. In countries such as China, the approval process for medical devices, especially for devices used for support or sustenance, is strict and time-consuming. Such a process has slowed the entry of medical devices into the market, thus restraining the growth. Companies in the market are increasingly investing in portable and wireless diagnostic respiratory devices. The trend is being driven by the ease of handling, cost-effectiveness, advanced features of these devices, and their suitability for use at home care organizations. Innovative technology-enabled portable respiratory devices are being launched into the market, which, unlike traditional devices, can be used for immediate diagnosis of vital signs, for example, the patients’ respiratory rate and the pulse rate. For instance, in 2019, the US Food and Drug Administration approved MediPines Corporation's non-invasive portable medical device, which provides clinicians with real-time pulmonary parameters and insights to support rapid triage and treatment decisions for respiratory conditions. In June 2020, AireHealth acquired BreathResearch for an undisclosed amount. The deal comprises the acquisition of IP, research, and patents, which include work on machine learning analytics for respiratory condition tracking. BreathResearch is a US-based company engaged in converting the airwaves of breathing into sound waves producing new respiratory analytics which improve health, fitness, and performance. Major players in the respiratory devices and equipment (diagnostic) market are ResMed. Inc, Medtronic PLC, Massimo Corporation, Fisher & Paykel Healthcare Limited, Koninklijke Philips N.V, Smiths Medical, GE Healthcare, Chart Industries, Philips Healthcare, and Becton Dickinson and Company. Asia Pacific was the largest region in the respiratory devices and equipment (diagnostic) market in 2021. North America was the second largest region in the global diagnostic respiratory devices and equipment market. Eastern Europe was the smallest region in the market. The regions covered in the global respiratory devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the respiratory devices and equipment (diagnostic) market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global diagnostic respiratory devices and equipment market is segmented - 1) By Product: Instruments and Devices, Assays and Reagents 2) By Test Type: Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests, Molecular Diagnostic Tests 3) By Disease Type: Chronic Obstructive Pulmonary Disease, Lung Cancer, Asthma, Tuberculosis, Others 4) By End-User: Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories, Others

The antiemetics and antinauseants market consists of sale of antiemetic and antinauseant drugs and related services. Antiemetic and antinauseant drugs prevent, control or treat, nausea and vomiting caused in general or by other medications, frequent motion sickness, infections, stomach flu or chemotherapy. These drugs block signal messages to the part of the brain that controls nausea and vomiting thus reducing the symptoms of nausea or vomiting. The main types of drugs in antiemetics and antinauseants are dopamine antagonists, nk1 receptor antagonist, antihistamines (h1 histamine receptor antagonists), cannabinoids, benzodiazepines, anticholinergics, steroids, 5-ht3 receptor antagonists and others. A dopamine antagonist, also referred as an anti-dopaminergic or a dopamine receptor antagonist, is a medication that works by blocking dopamine receptors. It is used in chemotherapy, motion sickness, gastroenteritis, general anaesthetics, opioid analgesics, dizziness, pregnancy, food poisoning, emotional stress, others and implemented in various sectors such as hospital, medical center, clinic, research institutes. The global antiemetics and antinauseants market size is expected to grow from $7.23 billion in 2021 to $ 7.71 billion in 2022 at a compound annual growth rate (CAGR) of 6.5%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global antiemetic and antinauseant market size is expected to reach $9.29 billion in 2026 at a CAGR of 4.8%. The antiemetics and antinauseants market is driven by the increase in the prevalence rate of cancer. Chemotherapy is one of the most recommended treatment to cure cancer, and chemotherapy-induced nausea and vomiting (CINV) are some of the side effects of the treatment. Antiemetics can help prevent CINV in about 60%-70% of patients. According to the WHO reports, the incidence of cancer globally has risen to 18.1 million new cases and 9.6 million deaths. According to another report by Centers for Disease Control and Prevention, about 650,000 cancer patients in the USA receive chemotherapy in an outpatient oncology clinic each year. The CINV caused by chemotherapy treatments is cured by using antiemetic and antinauseant drugs like Dolasetron (Anzemet), Ranitidine (Zantac) and other serotonin 5-HT3 receptor types of antagonists. Increase in the incidence of cancer will increase demand for antiemetics and antinauseants, thereby driving revenue for market. Lack of awareness about the variety of antiemetic and antinauseant drugs that are available in the market among the practitioners restrains the market. Despite the presence of a range of drugs, the practitioners prescribe the similar drugs to treat patients with different conditions of nausea. Popularity of only a few drugs leads to lower the demand of other drugs and thus restricts the overall growth of this market. For example, the American Society of Clinical Oncology released its first guideline in the ‘Choosing Wisely’ (CW) campaign to prevent and discourage the overuse of expensive and similar kind of antiemetic drugs for all ailments. Manufacturers are exploiting nanotechnology in the antiemetics and antinauseants market to deliver therapeutic agents to specific targeted sites in a controlled manner through Nano medicine and Nano delivery systems. Nano medicine is the medical application of nanotechnology which uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. The antiemetic and antinauseant drugs manufacturers are inclining more towards the use of Nano medicine or Nano drug to make the drug effective and increase their revenues. For instance, Merck & Co., an American multinational pharmaceutical company manufactured Aprepitant under the brand name Emend. It is first FDA-approved drug for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) that uses nanotechnology to increase the absorption of the drug more easily and efficiently. The antiemetics and antinauseants market is regulated by government agencies such as US Food and Drug Administration. In the USA, title 21 of Food and Drug Administration department of health and human services, U.S., part 336, contains conditions that all the Antiemetic and Antinauseant drugs are required to fulfill in order to remain in the market such as definition, regulations, and regulations related to labeling of the antiemetic drug products. Major players in the antiemetics and antinauseants market are Johnson & Johnson, Sanofi-Aventis, Pfizer, GlaxoSmithKline, Abbott Laboratories, Eli Lilly and Company, Merck, Eisai, Bristol-Myers Squibb and SRS Pharmaceuticals. North America was the largest region in the drugs for antiemetics and antinauseants market in 2021. The Middle East is expected to be the fastest growing region in the antiemetic and antinauseant market during the forecast period. The regions covered in the antinauseants and antiemetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antiemetics and antinauseants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global antiemetics and antinauseants market is segmented - 1) By Drug: Dopamine Antagonists, NK1 Receptor Antagonist, Antihistamines (H1 Histamine Receptor Antagonists), Cannabinoids, Benzodiazepines, Anticholinergics, Steroids, 5-HT3 Receptor Antagonists, Others 2) By Application: Chemotherapy, Motion Sickness, Gastroenteritis, General Anaesthetics, Opioid Analgesics, Dizziness, Pregnancy, Food Poisoning, Emotional Stress, Others 3) By End-User: Hospital, Medical Center, Clinic, Research Institutes

The dermatitis market consists of sales of dermatitis drugs such as corticosteroids, calcineurin inhibitors, PDE4 inhibitors which are used to cure inflammation of the outer layer of the body, characterized by itchy rashes on swollen and reddened skin. Some of the major dermatitis drugs include Triamcinolone, Clobetasol, Betamethasone, Hydrocortisone, Fluocinonide and Clobex. The main classes of drugs in dermatitis are corticosteroids, emollients/moisturizers, antihistamines, calcineurin inhibitors, antibiotics, immunomodulators and interleukin inhibitors. Corticosteroids are a group of steroid hormones generated by vertebrates' adrenal cortex, and also synthetic equivalents of these hormones. The different routes of administrations include topical, oral, injectable and is used in cancer, blood disorders, chronic diseases, infectious diseases. It is distributed through various channels such as hospital, retail pharmacies, drug stores, online or mail pharmacies The global dermatitis market size is expected to grow from $5.92 billion in 2021 to $6.37 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global dermatitis market is expected to reach $8.06 billion in 2026 at a CAGR of 6.1%. Growth in atopic dermatitis market is primarily driven by the increasing global prevalence of the disease. Prevalence of dermatitis in children is estimated to be around 15-20% while it is 1-3% in adults. The rising cases of food allergies are adding to the prevalence of dermatitis which ultimately leads to the increase in demand for the medicines to cure this disease. For example, according to the allergy asthma network 2020, approximately 31.6 million people in the United States have some form of atopic dermatitis. The prevalence of atopic dermatitis globally in children have 15-20 percent and in adults have 1 to 3 percent. The strict government regulations are one of the restraints for the dermatitis drug market. Atopic Dermatitis (eczema) usually occurs at a very early stage (0-5 years). In order to find the efficacy and efficiency of drug, it has to be tried on the every type of patients. The effects of certain drugs in adults are quite different than in children, as a reason result of the clinical trial cannot be used for the production of drug that will be served to the children. This hinders the research and requires more efforts in clearing regulation set by FDA. For example, as the patient population is largely children, FDA in its CFR Code Title 21, Part 50 Protection of Human Subjects, and subpart D has laid down guidelines for the additional safeguard for children in clinical investigation. The regulation is in compliance with Children’s Health Act of 2000 that requires all the children subjected to clinical trial be given additional protection. The dermatitis market has witnessed a trend of increasing mergers and acquisitions (M&As), done with the purpose of business expansion and increasing visibility. M&As are playing a significant role in today's world and are assumed to expand this market in the years to come. The vendors in this industry are focusing on collaboration and partnerships to expand their portfolio and improve market presence. Companies are also strategically making M&As with a view to reduce competition and increase the scalability of their business. For example, Stiefel Laboratories has been able to successfully widen its global reach after it was acquired by Glaxo Smith Kline. Also Biofrontera, Inc., a specialist in dermatology market acquired Cutanea Life Sciences, Inc.in 2019 for $7.3 million to increase their capital base and scale the business. The dermatitis drugs market is governed by several regulatory bodies that require the drug manufacturers to get approvals from the concerned authorities before launching their medicines into the market. Two such major regulatory bodies are PMDA (Japan) and CDSCO (India) that carry out quality checks before declaring the drugs suitable for consumption. PMDA reviews the products with an aim to ensure safety, quality and efficacy of pharmaceuticals and then approves the products that are suitable in every parameter. Similarly CDSCO is the central drug authority that is responsible for the approval of new drugs in India. These tedious approval processes makes the drugs more effective and safe, thereby having a positive impact on the dermatitis drugs market. Major players in the dermatitis market are LEO Pharma A/S, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Bayer HealthCare, Encore Dermatology Inc., Meda Pharmaceuticals, Allergan Plc. (Republic of Ireland) and Bristol-Myers Squibb. North America is the largest region in the dermatitis market in 2021. The Middle East is expected to be the fastest growing region in the global dermatitis market during the forecast period. The regions covered in the global dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global dermatitis market is segmented - 1) By Drug Class: Corticosteroids, Emollients/Moisturizers, Antihistamines, Calcineurin Inhibitors, Antibiotics, Immunomodulators, Interleukin Inhibitors 2) By Distribution Channel: Hospital, Retail Pharmacies, Drug Stores, Online or Mail Pharmacies 3) By Route of Application: Topical, Oral, Injectable 4) By Application: Cancer, Blood Disorders, Chronic Diseases, Infectious Diseases

Respiratory Masks (N95 Respirators, Surgical Masks, And Others) Market Definition

The market for respiratory masks (N95 respirators, surgical masks, and others) consists of sales of N95 respirators, surgical masks and other face masks used as personal protective equipment to protect the wearer from airborne particles and from liquid contaminating the face, or to ensure the wearer does not contaminate the area around them. The market consists of revenue generated by the company’s manufacturing the N95 respirators and surgical face masks by the sale of these products. N95 respirator is defined as a personalized protective respiratory device that protects the wearer from airborne and liquid contamination. These types of masks are predominantly used in the industrial or the healthcare sector, to protect workers from various respiratory and airborne diseases. N95 respirator is designed to filter at least 95% of airborne particles. Surgical masks are loose fitting, usually disposable devices which are commonly used in healthcare settings to protect doctors and other medical staff from the risk of an infection. These are single-use items and are usually disposed after being used once. Comfort masks or dust masks are a flexible pad held over the nose and mouth by elastic or rubber straps to protect the user against dusts encountered during construction or cleaning activities. They are also increasingly used in high pollution regions.

Anti-Asthmatic and COPD Drugs Definition

The anti-asthmatics and COPD drugs market consists of sales of anti-asthmatics and COPD drugs by entities (organizations, sole traders and partnerships) that manufacture anti-asthmatics and COPD drugs which are used to prevent and treat asthma and chronic obstructive pulmonary disease (COPD). The anti-asthmatics and COPD drug industry includes establishments that manufacture anti-asthmatics and COPD drugs such as bronchodilators, anti-inflammatory drugs, monoclonal antibodies and combination drugs. Asthma is a condition that causes the airways in the body to narrow and swell and generate extra mucus. This can make breathing difficult, resulting in coughing, wheezing on exhalation and shortness of breath. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes airflow obstruction in the lungs. Breathing difficulties, cough, mucus production and wheezing are all symptoms.

The respiratory diseases drugs market consists of sales of respiratory diseases drugs and related services by entities (organizations, sole traders and partnerships) that produce drugs to treat respiratory diseases such as asthma, acute bronchitis, emphysema, cystic fibrosis and other diseases. This industry includes establishments that produce anti-asthmatics and COPD drugs to prevent acute attacks caused by respiratory diseases and cough and cold preparations to treat cough and cold. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The main types of respiratory diseases drugs are anti-asthmatics and copd drugs, cough and cold preparations. Any medication that relieves the symptoms of asthma is considered an anti-asthmatic drugs. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global respiratory diseases drugs market size is expected to decline from $142.57 billion in 2021 to $154.79 billion in 2022 at a compound annual growth rate (CAGR) of 8.6%. The change in the respiratory diseases drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The respiratory diseases drugs market is expected to reach $292.01 billion in 2026 at a CAGR of 17.2%. During the forecast period, the growth of the respiratory diseases drugs market will be restrained by patent expiration of branded respiratory diseases drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Companies in the respiratory drugs market are offering drugs for customized individual treatment for better treatment against respiratory diseases. Personalized medicine, also referred to as precision medicine, aims to provide medical care according to the patient’s individual characteristics and genetic makeup. Precision therapies are increasingly being adopted in the respiratory drugs market as firms increasingly let go of the one-size-fits-all model for common respiratory conditions. Companies such as GSK, Teva Pharmaceuticals and AstraZeneca have already invested in personalized medicine for respiratory issues such as asthma. For example, PTC Therapeutics, is developing a drug, which aims to cater to a respiratory mutation which affects about 10% of the population. Companies manufacturing respiratory drugs are increasingly using biomarkers in the drug development process to reduce the time taken to bring the product into the market. Biomarkers are biological indicators which are objectively measured and evaluated for biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. It can also help predict the drug efficacy faster than conventional clinical endpoints, the point at which an undesired or abnormal effect of the drug is observed indicating withdrawal from therapy. Companies in this market are investing in the development of biomarkers for use in various activities such as tracking drug activity, the pharmacodynamics (relationship between the drug concentration at the site of action and the biochemical and physiological effect) of drugs and to study diseases and treatment pathways. Companies such as Genentech and Janssen are increasingly investing in the use of biomarkers for understanding the efficacy of a potential respiratory drug. For example, Janssen has partnership with U-BIOPRED (unbiased biomarkers in prediction of respiratory disease outcomes), a group in Europe that aims to understand more about severe asthma. Major companies in the respiratory diseases market include Boehringer Ingelheim GmbH, Vertex Pharmaceuticals, AstraZeneca, Pfizer Inc., GlaxosmithKline, Novartis AG, Johnson & Johnson, Reckitt Benckiser Group plc, Mylan N.V., and Sanofi S.A. North America was the largest region in the respiratory diseases drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the respiratory diseases drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the respiratory diseases drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global respiratory diseases drugs market is segmented - 1) By Type: Anti-Asthmatics and COPD Drugs, Cough and Cold Preparations 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The COVID-19 drug-associated APIs market consists of sales of active pharmaceutical ingredients used in the manufacturing of COVID-19 drugs. The active pharmaceutical ingredients are chemicals which are responsible for pharmacological activity in the human body and are used as a base in pharmaceutical drug or medicine. The APIs used for the preparation of COVID-19 drugs and include Azithromycin, Fentanyl, Albuterol, Cisatracurium and others. The main classes of drugs in COVID-19 drug-associated APIs are antimalarials, bronchodilators, antibiotics, antivirals and others. Antimalarial drugs, or simply antimalarials, are antiparasitic chemical agents which can be utilized to cure or prevent malaria. They are generally organically sourced. The different types of drugs include generic, branded and involves various modes of businesses such as captive API, merchant API. The global COVID-19 drug associated APIs market size is expected to grow from $5.55 billion in 2021 to $5.99 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The COVID-19 drug associated APIs market is expected to reach $7.55 billion in 2026 at a CAGR of 6%. High demand for some antiretrovirals, antimalarials, sedatives, bronchodilators, and other respiratory drugs drives the demand for the active pharmaceutical ingredients (APIs) used in the production of COVID-19 drugs. Active pharmaceutical ingredients are the biologically active component used in manufacturing pharmaceutical drugs. Remdesivir and Favipiravir are two common antiviral medications used currently for the treatment of COVID-19 patients. Remdesivir is a medication approved for emergency use in the USA and Japan for the treatment of COVID-19 patients. Remdesivir gained emergency use authorization (EUA) from the FDA on May 1, 2020, based on its preliminary data showing a faster time to recovery in hospitalized patients with several diseases. Favipiravir, which used to treat influenza in Japan, has also shown a positive effect on COVID patients. As COVID-19 is a respiratory ailment, the demand for bronchodilators spiked significantly. Therefore, the increasing demand for antivirals, antimalarials, and bronchodilators is projected to boost the demand for COVID-19 associated drug APIs market over the forecast period. The disruptions caused by the COVID-19 outbreak in the supply chain of medical products limited the growth of the COVID-19 drug-associated APIs market in the past few months. The source for APIs plays a crucial part in the strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, with nearly 30% generic APIs used in the USA. The restrictions imposed on the export of pharma products owing to COVID-19 supply chain disruptions restricted the market growth. For instance, India imposed an export ban on 26 pharma products and medical devices in March 2020. The ban was imposed attributing to the supply chain disruptions on API and other bulk drugs due to restrictive measures such as lockdown and closure of factories in many countries across the globe to ensure that the disease spread is contained. Thus, shortages caused by the disruptions in supply chains and restrictions imposed on the export of pharma products impacted the growth of the COVID-19 drug-associated APIs market over the last few months. Key players operating in the pharmaceutical industry that manufactures COVID-19 drug associated APIs are focusing on strategies such as plant capacity or production capacity expansion to meet the increasing demand due to the rising number of coronavirus cases across the globe. For instance, in March 2020, Alembic Pharmaceuticals Ltd announced that the company is ramping up the production for the company’s production for azithromycin to 20 tons per month. Likewise, In April 2020, FUJIFILM Corporation announced the expansion of its manufacturing capacity and increase in the production of influenza antiviral Avigan Tablet (Favipiravir) by nearly 2.5 times by the end of July. Avigan is currently undergoing clinical trials testing its safety and efficacy for the treatment of COVID-19 patients. In February 2020, Dr. Reddy Labs announced the acquisition of the branded generics business of Wockhardt for an amount of $242 million (INR 1,850 crore). The acquisition is expected to scale-up the former company’s presence in home markets including India, Nepal, Sri Lanka, Bhutan, and the Maldives. The Wockhardt business consists of a product portfolio of 62 brands and in multiple therapy fields such as dermatology, neurology, respiratory, VMS, pain, gastroenterology, and vaccine. Wockhardt Ltd. was founded in 1999 and is a global biotechnology and pharmaceutical company based in Mumbai, India. Major players in the COVID-19 drug-associated APIs market are Dr. Reddy's Laboratories, Lianyungang Guike Pharmaceutical, Alembic Pharmaceutical, Wockhardt Ltd, Sandoz Srl, Lupin Limited, Aurobindo Pharma Ltd., Shanghai Shyndec Pharmaceutical (Haimen) Co Ltd, and Yatai Pharma. North America is the largest region in the COVID-19 drug-associated APIs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the COVID-19 drug associated APIs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the COVID-19 drug-associated APIs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global COVID-19 drug associated APIs market is segmented - 1) By Drug Class: Antimalarials, Bronchodilators, Antibiotics, Antivirals, Others 2) By Synthesis Type: Synthetic, Biotech 3) By Business Mode: Captive API, Merchant API